BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2517322)

  • 21. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
    J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis and management of membraneous nephropathy.
    Pahari DK; Das S; Dutta BN; Banerjee D
    J Assoc Physicians India; 1993 Jun; 41(6):350-1. PubMed ID: 8005970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine A in treatment of membranous lupus nephropathy.
    Hu W; Liu Z; Shen S; Li S; Yao X; Chen H; Li L
    Chin Med J (Engl); 2003 Dec; 116(12):1827-30. PubMed ID: 14687467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective treatment administration of cyclophosphamide in membranous nephropathy.
    Dede F; Ayili D; Sahiner S
    J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study.
    Haas M; Mayer G; Wirnsberger G; Holzer H; Ratschek M; Neyer U; Neuweiler J; Kramar R; Schneider B; Breiteneder-Geleff S; Regele HM; Hörl WH; Kerjaschki D
    Wien Klin Wochenschr; 2002 Feb; 114(4):143-7. PubMed ID: 12060980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
    Shearman JD; Yin ZG; Aarons I; Smith PS; Woodroffe AJ; Clarkson AR
    Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis.
    Pokhariyal S; Gulati S; Prasad N; Sharma RK; Singh U; Gupta RK; Mittal S; Mehta B
    J Nephrol; 2003; 16(5):691-6. PubMed ID: 14733415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy.
    Ponticelli C; Zucchelli P; Imbasciati E; Cagnoli L; Pozzi C; Passerini P; Grassi C; Limido D; Pasquali S; Volpini T
    N Engl J Med; 1984 Apr; 310(15):946-50. PubMed ID: 6366560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis?
    Davenport A; Maciver AG; Hall CL; MacKenzie JC
    Clin Nephrol; 1994 May; 41(5):271-6. PubMed ID: 8050206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency.
    du Buf-Vereijken PW; Wetzels JF
    Nephrol Dial Transplant; 2006 Feb; 21(2):389-96. PubMed ID: 16234291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of low-dose chlorambucil in nephrotic patients with idiopathic membranous nephropathy.
    Idasiak-Piechocka I; Oko A; Łochyńska-Bielecka K; Skrobańska B
    Kidney Blood Press Res; 2009; 32(4):263-7. PubMed ID: 19776643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Boumpas DT; Tassiulas IO; Fleisher TA; Vaughan E; Piscitelli S; Kim Y; Pucino F; Balow JE; Austin HA
    Clin Nephrol; 1999 Aug; 52(2):67-75. PubMed ID: 10480216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
    Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
    Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remissions and relapses in idiopathic membranous nephropathy.
    Ponticelli C; Passerini P; Altieri P; Locatelli F; Pappalettera M
    Nephrol Dial Transplant; 1992; 7 Suppl 1():85-90. PubMed ID: 1337188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children.
    Ozdamar SO; Gucer S; Tinaztepe K
    Pediatr Nephrol; 2003 Jan; 18(1):23-8. PubMed ID: 12488986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome.
    Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D
    Nephrol Dial Transplant; 2006 Nov; 21(11):3127-32. PubMed ID: 16968719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
    Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
    Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
    Kibriya MG; Tishkov I; Nikolov D
    Nephrol Dial Transplant; 1994; 9(2):138-43. PubMed ID: 8190328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Willems HL; Wetzels JF
    Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.